Pliant Therapeutics’ experimental oral anti-fibrotic therapy bexotegrast has received orphan drug designation from the European Medicines Agency (EMA) as a potential treatment for idiopathic pulmonary fibrosis (IPF), the company announced. EMA gives this designation to therapies that have the potential to improve care for conditions that affect fewer…
With just a few days remaining before Christmas, not much has changed this year in the search for a cure for pulmonary fibrosis (PF). Scientists continue to pursue theories searching for a clue that will lead to a cure or even more effective therapies. But even research that does…
Curveball is a baseball term, but it also can apply to life when something surprising or unexpected happens. It’s been several months since my last column, and in that time, life has thrown me a curveball. I’ve been constantly battling my illness, and so much has happened. I am…
Medicom Technologies is partnering with the Open Source Imaging Consortium (OSIC) to extend access to anonymized clinical information — key for the detection and diagnosis of rare diseases, such as idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). Both organizations…
Vicore Pharma has launched the pivotal part of its COMPANION study to test Almee, a digital app designed to help people with pulmonary fibrosis (PF) cope with anxiety. Almee is a digital cognitive behavioral therapy (CBT) developed by Vicore…
I have a love-hate relationship with pulmonary rehabilitation. With rapidly declining lungs due to idiopathic pulmonary fibrosis (IPF), it’s hard to exercise. Despite this, exercise is one of the most important things a patient with IPF should be doing consistently, so I try to love it. I…
How is it December already? In the retail world, the holiday season seems to begin earlier every year. It felt like ads for Thanksgiving and Christmas started airing around Labor Day this year here in the United States. Last year, I noticed my thoughts turned to my donor family more…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ifenprodil, the active agent in NP-120, an investigational oral medicine for idiopathic pulmonary fibrosis (IPF). This designation gives Algernon Pharmaceuticals, as the therapy’s developer, certain incentives including tax credits, fee waivers, and a guarantee for…
The first-of-its-kind Vicore COMPANION Study is now recruiting participants across the U.S. to test Almee, a new artificial intelligence (AI) app designed to help people with pulmonary fibrosis (PF) manage their anxiety. Developed by Vicore Pharma, Almee is an investigational digital cognitive behavioral therapy (CBT) that uses…
Life is full of important reflections. As a child and teenager, I moved at lightning speed, never wanting to miss out on an opportunity. Since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016, I’ve been forced to slow down, as my declining lungs no longer allow…
Get regular updates to your inbox.
